Health Care • Biopharmaceuticals, GLP-1/GIP Cardiometabolic & Oncology • SIC 2834
$1,417.54 ▲ +43.84
(+3.19%)
MKT CAP: $1.34T • VOL: 5.03M
52W L $810 52W H $1,450
LLY // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2026-02-12 | FY 2024
FILED 2026-02-12 | FY 2023
FILED 2026-02-12 | FY 2022
FILED 2025-02-19 | FY 2021
FILED 2024-02-21 |
|---|---|---|---|---|---|
| Revenue (Total Sales) | $65.18B | $45.04B | $34.12B | $28.54B | $28.32B |
| YoY Revenue Growth % | +44.7% | +32.0% | +19.6% | +0.8% | +15.4% |
| Gross Profit | $54.13B | $36.63B | $27.04B | $21.91B | $21.01B |
| Gross Margin % | 83.0% | 81.3% | 79.3% | 76.8% | 74.2% |
| Research & Development (R&D) | $13.34B | $10.99B | $9.31B | $7.19B | $6.93B |
| Operating Income (EBIT) | $25.73B | $12.68B | $6.55B | $6.81B | $6.16B |
| Operating Margin % | 39.5% | 28.1% | 19.2% | 23.9% | 21.7% |
| Net Income (GAAP) | $20.64B | $10.59B | $5.24B | $6.24B | $5.58B |
| EBITDA (Normalized) | $27.73B | $14.45B | $8.08B | $8.33B | $7.70B |
| Diluted EPS ($/sh) | $22.95 | $11.71 | $5.80 | $6.90 | $6.12 |
| Operating Cash Flow (OCF) | $16.81B | $8.82B | $4.24B | $7.59B | $7.37B |
| Capital Expenditures (CapEx) | — | — | — | — | — |
| Free Cash Flow (FCF) | $16.81B | $8.82B | $4.24B | $7.59B | $7.37B |
| FCF Margin % | 25.8% | 19.6% | 12.4% | 26.6% | 26.0% |
| Return on Invested Capital (ROIC %) | 32.9% | 22.4% | 15.6% | 21.7% | 22.1% |
| Cash & Short-Term Equivalents | $7.27B | $3.27B | $2.82B | $2.07B | $3.82B |
| Total Debt (Short + Long Term) | $42.50B | $33.64B | $25.23B | $16.24B | $16.88B |
| Total Stockholders' Equity | $26.54B | $14.27B | $10.77B | $10.65B | $8.98B |
| LINE ITEM (USD / %) | Q3 2026
FILED 2026-10-29 | Q2 2026
FILED 2026-08-05 | Q1 2026
FILED 2026-04-30 | Q4 2025
FILED 2026-02-12 | Q3 2025
FILED 2026-10-29 | Q2 2025
FILED 2026-08-05 |
|---|---|---|---|---|---|---|
| Revenue (Total Sales) | $24.40B | $22.97B | $19.80B | $19.29B | $17.60B | $15.56B |
| YoY Revenue Growth % | +38.6% | +47.7% | +55.5% | +42.5% | +53.9% | +37.6% |
| Gross Profit | $20.46B | $19.71B | $16.22B | $15.92B | $14.59B | $13.11B |
| Gross Margin % | 83.9% | 85.8% | 81.9% | 82.5% | 82.9% | 84.3% |
| Research & Development (R&D) | $4.25B | $3.82B | $3.51B | $3.80B | $3.47B | $3.34B |
| Operating Income (EBIT) | $8.41B | $9.25B | $8.85B | $8.27B | $7.23B | $6.78B |
| Operating Margin % | 34.5% | 40.3% | 44.7% | 42.8% | 41.1% | 43.6% |
| Net Income (GAAP) | $6.45B | $7.09B | $7.40B | $6.64B | $5.58B | $5.66B |
| EBITDA (Normalized) | $9.25B | $10.17B | $9.36B | $9.09B | $7.96B | $7.45B |
| Diluted EPS ($/sh) | $7.22 | $7.94 | $8.26 | $7.39 | $6.21 | $6.29 |
| Operating Cash Flow (OCF) | $11.40B | $10.69B | $5.33B | $3.23B | $8.84B | $3.09B |
| Capital Expenditures (CapEx) | — | — | — | — | — | — |
| Free Cash Flow (FCF) | $11.40B | $10.69B | $5.33B | $3.23B | $8.84B | $3.09B |
| FCF Margin % | 46.7% | 46.5% | 26.9% | 16.7% | 50.2% | 19.8% |
| Return on Invested Capital (ROIC %) | 31.3% | 36.6% | 40.4% | 42.3% | 40.5% | 39.1% |
| Cash & Short-Term Equivalents | $4.88B | $8.95B | $5.28B | $7.27B | $9.79B | $3.38B |
| Total Debt (Short + Long Term) | $49.50B | $54.91B | $43.37B | $42.50B | $42.51B | $39.90B |
| Total Stockholders' Equity | $40.27B | $33.88B | $31.20B | $26.54B | $23.79B | $18.27B |